Sebastian A. Brunemeier is a biotech VC and company builder focused on longevity & regenerative medicine. He is Co-Founder and General Partner of Healthspan Capital, and CEO and Founder of ImmuneAGE Pharma (stealth), focused on immune system rejuvenation. Over the last 5 years, he has co-founded 4 longevity biotech (“LongBio”) companies with a total equity value of >$700M. He was Co-Founder and Chief Investment Officer at Cambrian Biopharma, Co-Founder and COO of Samsara Therapeutics, and Principal at Apollo Health Ventures (the first and largest ageing-focused venture capital fund in the world with $200M AUM). Altogether, these organizations have raised ±$400M in the last 4 years. He was a Fulbright Fellow on the biology of ageing, a Skaggs-Oxford Scholar at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. His education includes partial DPhil (PhD) training in the biochemistry of ageing at the University of Oxford as a Clarendon Scholar and a Master’s in Life Science Business Management and Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. He served as a trustee of the British Society for Research on Aging, a mentor at The New York Academy of Sciences, and as an advisor or board member to VitaDAO/Molecule.to, Equator Therapeutics, Revivo Therapeutics, Shift Biosciences, Deciduous Therapeutics, and McKinsey & Company.